Focal Brachytherapy in Patients With Selected "Low-risk" Prostate Cancer - a Phase-II-trial

This trial examines the feasibility and toxicity of focal brachytherapy in patients with low-risk prostate cancer.

Trial Details

NCT ID
NCT02391051
Phase
PHASE2
Sponsor
University of Erlangen-Nürnberg Medical School
Status
RECRUITING
Cancer Type
Prostate Cancer
Interventions
  • HDR-Brachytherapy
Locations (sample)
  • Erlangen, Germany|49.59099,11.00783

Key Eligibility Criteria

  • Histologically confirmed prostate cancer
  • Gleason Score of index lesion ≤ 6 (3+3)
  • Tumor stage: cT1-2a cN0 cM0
  • Unilateral affection; index lesion ≤ 0.5ml with or without clinically non-significant lesion contralateral. No more than 25% of the punch should be…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Prostate Cancer Trials on Trialify →